|Manufacturer:||Astellas Pharma US, Inc.|
|Other Info:||Ansyr® is a registered trademark of Hospira, Inc.Marketed by:Astellas Pharma US, Inc.Deerfield, IL 60015-2548Manufactured by:Hospira, Inc.Lake Forest, IL 60045 USA|
Intravenous Adenocard (adenosine injection) is indicated for the following.Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome).
When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver), should be attempted prior to Adenocard administration.It is important to be sure the Adenocard solution actually reaches the systemic circulation (see DOSAGE AND ADMINISTRATION).Adenocard does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm.In the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following Adenocard administration.
Adenocard (adenosine injection) exerts its effect by decreasing conduction through the A-V node and may produce a short lasting first-, second- or third-degree heart block.
Appropriate therapy should be instituted as needed.
Patients who develop high-level block on one dose of Adenocard should not be given additional doses.
Because of the very short half-life of adenosine, these effects are generally self-limiting.Transient or prolonged episodes of asystole have been reported with fatal outcomes in some cases.
Rarely, ventricular fibrillation has been reported following Adenocard administration, including both resuscitated and fatal events.
In most instances, these cases were associated with the concomitant use of digoxin and, less frequently with digoxin and verapamil.
Although no causal relationship or drug-drug interaction has been established, Adenocard should be used with caution in patients receiving digoxin or digoxin and verapamil in combination.Appropriate resuscitative measures should be available.